Ljubljana / Prague – 26 August 2026 – ARX Equity Partners (“ARX”), a leading Central European private equity firm, today announced the acquisition of a majority stake in Medicofit, fizioterapija d.o.o. (“Medicofit” or the “Company”), Slovenia’s foremost private provider of integrated musculoskeletal care. The transaction marks the first institutional private equity investment into Slovenia’s private physiotherapy sector and establishes a platform for accelerated regional expansion. Financial terms of the transaction were not disclosed.
Founded in Ljubljana in 2021 by Jaka Plantan and Nejc Šimenko, Medicofit has, in under five years, established itself as the reference provider for structured, evidence-based rehabilitation in Slovenia. The Company delivers an integrated clinical model spanning diagnostics, physiotherapy, kinesiology and preventive care, and has built a reputation for measurable clinical outcomes, patient-centred protocols and operational rigour uncommon in the regional market.
A Milestone Transaction for the Region
The transaction represents a strategic entry point for institutional capital into a segment historically dominated by fragmented, owner-operated practices. It signals a broader thesis: that Central European private healthcare services – particularly outpatient musculoskeletal care – are approaching institutional scale and warrant the operating discipline and capital that specialised investors can bring.
For Medicofit, the partnership with ARX supports a defined next phase: deepening clinical capabilities, expanding geographic footprint, and building the operational infrastructure required to serve a materially larger patient base across Slovenia and the wider Adriatic region.
Leadership and Governance
Co-founder Jaka Plantan will assume the role of Chief Executive Officer, leading the Company’s next chapter alongside co-owner Marko Stojanović, who continues as Chief Physiotherapist and clinical lead. Both remain significant shareholders alongside ARX. Day-to-day operational leadership continues under Nikita Belopavlovič, Head of Operations, who oversees clinical operations, commercial performance and team development.
As part of the transition, outgoing director Nejc Šimenko exits both his executive role and shareholder position. The Company thanks him for his contribution during its formative period.